Area of research
Rheumatology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Systemic Lupus Erythematosus Research, Vasculitis and related conditions, Rheumatoid Arthritis Research and Therapies, and Autoimmune and Inflammatory Disorders Research.
Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.
Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis.
Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.
Effectiveness and safety of low-energy shock wave therapy for digital ulcers associated with systemic sclerosis: A Phase 3 pivotal clinical trial.
Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study).
Rheumatoid Factor Predicts Long-Term Retention Associated With Effectiveness of Certolizumab Pegol in Patients With Rheumatoid Arthritis: A Two-Center Retrospective Study.
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.
Enthesitis as an initial presentation of vascular Behçet's syndrome: a case-based review.
Successful management of interstitial lung disease in dermatomyositis complicated by malignancy: a case-based review.
"Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis: case report and literature review".
Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
Dysbiosis in Takayasu arteritis complicated with infectious endocarditis following tocilizumab administration.
Development of severe colitis in Takayasu arteritis treated with tocilizumab.
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
Genetic determinants and an epistasis of<i>LILRA3</i>and HLA-B*52 in Takayasu arteritis